News | Events | Publications

Holiday Message From Tools4Patient CEO, Dominique Demolle

December 24, 2019

During this season of joy and reflection, it is our pleasure at Tools4Patient to offer our warmest wishes for a safe, happy

View

Tools4Patient Selected as Finalist in 2019 Clinical Trials Innovations Challenge

September 16, 2019

Tools4Patient’s Placebell©™ technology has been selected as a finalist in the 2019 Clinical Trials Innovation Challenge sponsored by IQVIA, Lundbeck, and LEO Innovation Lab.

View

ISCTM 16th Annual Scientific Meeting

The International Society for CNS Clinical Trials and Methodology (ISCTM) is a multi-disciplinary independent organization, devoted to promoting advances that address strategic clinical, regulatory, methodological and policy challenges that arise

View

DIA Europe – Healthcare Conference

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the

View

Characterizing Personality Traits Related to the Placebo Response Using the MPsQ Questionnaire

November 19, 2019

Learn more about the development of the MPsQ and the its use as part of the Placebell©™ technology.

Read More

Is the placebo effect contagious between investigators and patients?

November 12, 2019

A recent study published in Nature Human Behavior developed a methodology to understand and assess the role of physician expectation on the placebo response. Read more about this study here.

Read More

Tools4Patient Introduces New Brand and Website

September 3, 2019

Tools4Patient is committed to our mission of developing predictive tools to optimize the evaluation of clinical-stage drugs. Along with our recent launch of Placebell©™ – a predictive algorithm focused on the placebo response – and our recent fundraising to support commercialization of Placebell©™ and further R&D, T4P is entering a new phase as a company.

Read More

The Case Against Excluding High Placebo Responders from Clinical Trials

March 10, 2019

Drug developers have been struggling with the placebo response for decades, as a strong placebo effect diminishes the ability to distinguish pharmacologic treatment efficacy of an experimental drug.

Read More

Modelling of PNP and OA Placebo Response: Working towards a unique model of the placebo response in chronic pain?

In analgesia randomized clinical trials (RCTs), the magnitude and the variability of the placebo response negatively impacts the ability to demonstrate superiority of active compounds compared to placebo. The first objective of this analysis was to investigate parameters influencing the placebo response in PNP as a way to control for this major confounding factor.

Identification Of Peripheral Neuropathic Pain Sensory Phenotypes Based On Specific Combinations Of Symptoms Identified With The NPSI (Neuropathic Pain Symptom Inventory)

One way to better personalized the treatment of peripheral neuropathic pain (PNP) would be to identify specific sensory phenotypes of patients responding to different classes of drugs.

Leveraging Historical Data For High-dimensional Covariate-adaptive Randomization, A Machine Learning Approach.

There is a continuous growth in data collected in clinical trials. Many of those patient’s characteristics are potential confounding factors. Ideally, these factors should be accounted for in the randomization process to balance study arms and reduce the variability of the estimated treatment effect.

Interview with Erica Smith, VP of Business Development at Biotech Showcase, San Francisco (January 2019).

Interview with Daniel Levine and Erica Smith, VP of Business Development on The Bio Report podcast (June 2019).

Interview with Andy Burrows of PC TV and Dominique Demolle, CEO at Partnerships in Clinical Trials, Europe (2017).

The Characterization of Individual Patient Placebo Response: Impact on the Clinical Study Power

A sophisticated method to identify placebo responders and reduce data variability due to the placebo response, providing drug developers with a tool to manage the placebo response without excluding high placebo responders.

Sign up to join our regular newsletter.
Be the first to receive the latest innovations and news from Tools4Patient.